Počet záznamů: 1
Edoxaban for Stroke Prevention in Atrial Fibrillation and Age-Adjusted Predictors of Clinical Outcomes in Routine Clinical Care
- 1.
SYSNO ASEP 0560446 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Edoxaban for Stroke Prevention in Atrial Fibrillation and Age-Adjusted Predictors of Clinical Outcomes in Routine Clinical Care Tvůrce(i) Kirchhof, P. (GB)
Pecen, Ladislav (UIVT-O) RID, SAI, ORCID
Bakhai, A. (GB)
De Asmundis, C. (BE)
de Groot, J. (BE)
Deharo, J. C. (FR)
Kelly, P. (IE)
Levy, P. (FR)
Lopez-De-Sa, E. (ES)
Monteiro, P. (PT)
Steffel, J. (CH)
Waltenberger, J. (DE)
Weiss, T. W. (AT)
Laeis, P. (DE)
Manu, M. C. (DE)
Souza, J. (DE)
De Caterina, R. (IT)Celkový počet autorů 18 Zdroj.dok. European Heart Journal-Cardiovascular Pharmacotherapy. - : Oxford University Press - ISSN 2055-6837
Roč. 9, č. 1 (2023), s. 47-57Poč.str. 11 s. Forma vydání Tištěná - P Jazyk dok. eng - angličtina Země vyd. GB - Velká Británie Klíč. slova Non-vitamin K oral anticoagulant ; Edoxaban ; Real-world ; Registry ; Atrial fibrillation Obor OECD Cardiac and Cardiovascular systems Způsob publikování Open access Institucionální podpora UIVT-O - RVO:67985807 UT WOS 000836165300001 EID SCOPUS 85144586435 DOI 10.1093/ehjcvp/pvac042 Anotace AIMS: Patients with atrial fibrillation (AF) treated with oral anticoagulation still suffer from cardiovascular complications including cardiovascular death, stroke, and major bleeding. To identify risk factors for predicting stroke and bleeding outcomes in anticoagulated patients, we assessed 2-year outcomes in patients with AF treated with edoxaban in routine care. We also report the age-adjusted risk predictors of clinical outcomes. METHODS AND RESULTS: The Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation (ETNA-AF) Europe (NCT02944019) is a prospective, multi-centre, post-authorisation, observational study with an overall 4-year follow-up conducted in 825 centres enrolling edoxaban-treated patients in 10 European countries. Of the 13 133 patients with AF (mean age: 73.6 ± 9.5 years), 5682 (43.3%) were female. At the 2-year follow-up, 9017/13 133 patients were still on edoxaban, 1830 discontinued treatment including 937 who died (annualised event rate of all-cause death was 3.87%). 518 (2.14%) patients died of cardiovascular causes, 234 (0.97%) experienced major bleeding and 168 (0.70%) experienced stroke or systemic embolic events (SEE). Intracranial haemorrhage was noted in 49 patients (0.20%). History of transient ischaemic attack (TIA) at baseline was the strongest predictor of ischaemic stroke or SEE (Wald χ2: 73.63, P < 0.0001). Low kidney function at baseline was the strongest predictor of major bleeding (Wald χ2: 30.68, P < 0.0001). History of heart failure (HF) was the strongest predictor of all-cause (Wald χ2: 146.99, P < 0.0001) and cardiovascular death (Wald χ2: 100.38, P < 0.0001). CONCLUSION: Patients treated with edoxaban in ETNA-AF-Europe reported low 2-year event rates in unselected AF patients. Prior stroke, reduced kidney function, and HF identify patients at high risk of stroke, bleeding and all-cause/cardiovascular death, respectively. Pracoviště Ústav informatiky Kontakt Tereza Šírová, sirova@cs.cas.cz, Tel.: 266 053 800 Rok sběru 2024 Elektronická adresa https://dx.doi.org/10.1093/ehjcvp/pvac042
Počet záznamů: 1